NRx Pharmaceuticals Reports Q2 EPS at 98c, Attracts First Group of Fundamental Biotechnology Investors

NRx Pharmaceuticals reported Q2 EPS of 98c, beating last year's 75c. The company has made progress with its lead programs and attracted its first group of biotechnology investors. The investors have contributed sufficient capital to reach regulatory inflection points and have purchased restricted common stock with a one-year lockup agreement. NRx has also received expanded Fast Track designation from FDA for its NRX-100 treatment and has filed an NDA for Accelerated Approval in bipolar depression and akathisia.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) reported a quarterly earnings per share (EPS) of 98 cents for the second quarter of 2025, exceeding last year's 75 cents. The company's financial performance reflects significant progress in its lead programs and strategic investments that are poised to accelerate regulatory milestones.

NRx Pharmaceuticals has made notable advancements in its lead programs, including NRX-100, a preservative-free intravenous ketamine formulation. The company received an expanded Fast Track designation from the FDA for NRX-100, addressing an unmet medical need in the treatment of suicidal ideation in depression, including bipolar depression. This designation represents a substantial expansion of the addressable market to approximately 13 million Americans annually [1].

The company has also filed an Abbreviated New Drug Application (ANDA) for NRX-100 and a Citizen’s Petition to remove Benzethonium Chloride (BZT), a toxic preservative, from intravenous ketamine products. Additionally, NRx Pharmaceuticals has submitted a patent application for its proprietary preservative-free formulation of NRX-100, which aims to confer orange-book exclusivity [1].

Furthermore, NRx Pharmaceuticals has initiated filing of a New Drug Application (NDA) for Accelerated Approval in bipolar depression and akathisia, reflecting the company's commitment to developing innovative treatments for mental health disorders. The company's efforts to expand its market potential and address unmet medical needs have been bolstered by the receipt of a Commissioner’s National Priority Voucher (CNPV) application, which could expedite the review process and potentially lead to accelerated approval of NRX-100 [1].

In addition to its regulatory accomplishments, NRx Pharmaceuticals has attracted its first group of biotechnology investors. The investors have contributed sufficient capital to reach expected regulatory inflection points and have purchased restricted common stock with a one-year lockup agreement. The strategic investment from the B Group Capital-led consortium of ultra-long-term healthcare specialist investors underscores the company's potential to scale and develop its HOPE Therapeutics business [1].

The company's strong financial performance and strategic initiatives position NRx Pharmaceuticals to continue delivering life-saving treatments to soldiers, first responders, veterans, and civilians in urgent need.

References:
[1] https://finance.yahoo.com/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-121000906.html